HUP0400120A2 - Mellékpajzsmirigy hormon és kalcitonin orális adagolására szolgáló gyógyászati készítmény - Google Patents

Mellékpajzsmirigy hormon és kalcitonin orális adagolására szolgáló gyógyászati készítmény

Info

Publication number
HUP0400120A2
HUP0400120A2 HU0400120A HUP0400120A HUP0400120A2 HU P0400120 A2 HUP0400120 A2 HU P0400120A2 HU 0400120 A HU0400120 A HU 0400120A HU P0400120 A HUP0400120 A HU P0400120A HU P0400120 A2 HUP0400120 A2 HU P0400120A2
Authority
HU
Hungary
Prior art keywords
calcitonin
parathyroid hormone
pharmaceutical composition
orally administering
administering parathyroid
Prior art date
Application number
HU0400120A
Other languages
English (en)
Inventor
Joseph Ault
Moise Azria
Simon David Bateman
James F. Mcleod
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0400120(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0400120A2 publication Critical patent/HUP0400120A2/hu
Publication of HUP0400120A3 publication Critical patent/HUP0400120A3/hu
Publication of HU229613B1 publication Critical patent/HU229613B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgya mellékpajzsmirigy-hormon (PTH) orális adagolásáraszolgáló gyógyászati készítmény, amelyre jellemző, hogy a betegnekszükség esetén hatékony mennyiségű PTH-t és hatékony mennyiségűkalcitonint adagolnak orálisan. A találmány lehetővé teszi a PTHorális adagolását anélkül, hogy hypercalcaemia, hypercalciuria ésvesekőbetegség mellékhatás lépne fel. Ó
HU0400120A 2001-06-01 2002-05-31 Oral administration of parathyroid hormone and calcitonin HU229613B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
PCT/EP2002/006017 WO2002098453A2 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin

Publications (3)

Publication Number Publication Date
HUP0400120A2 true HUP0400120A2 (hu) 2005-04-28
HUP0400120A3 HUP0400120A3 (en) 2012-09-28
HU229613B1 HU229613B1 (en) 2014-03-28

Family

ID=23136525

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400120A HU229613B1 (en) 2001-06-01 2002-05-31 Oral administration of parathyroid hormone and calcitonin

Country Status (25)

Country Link
US (2) US20040186050A1 (hu)
EP (1) EP1397156B1 (hu)
JP (2) JP5073153B2 (hu)
KR (3) KR20040007617A (hu)
CN (2) CN1512892A (hu)
AT (1) ATE356631T1 (hu)
AU (2) AU2002344371B2 (hu)
BR (1) BRPI0209748B1 (hu)
CA (1) CA2446929C (hu)
CO (1) CO5540323A2 (hu)
CZ (1) CZ307145B6 (hu)
DE (1) DE60218842T2 (hu)
EC (1) ECSP034858A (hu)
ES (1) ES2282436T3 (hu)
HU (1) HU229613B1 (hu)
IL (2) IL158777A0 (hu)
MX (1) MXPA03011027A (hu)
NO (1) NO330093B1 (hu)
NZ (1) NZ529439A (hu)
PL (1) PL211976B1 (hu)
PT (1) PT1397156E (hu)
RU (1) RU2300392C2 (hu)
SK (1) SK287697B6 (hu)
WO (1) WO2002098453A2 (hu)
ZA (1) ZA200308625B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040007617A (ko) 2001-06-01 2004-01-24 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
CA2453646C (en) 2001-08-17 2008-09-30 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
AR058053A1 (es) 2005-09-19 2008-01-23 Toole Doris C O Formas cristalinas polimorficas de la sal de di- sodio del acido n- (5 -clorosaliciloil)-8- aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN101309674A (zh) * 2005-11-17 2008-11-19 诺瓦提斯公司 药物组合物
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
CN104857505A (zh) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
ES2823233T3 (es) * 2008-08-18 2021-05-06 Entera Bio Ltd Métodos y composiciones para la administración oral de proteínas
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
JP6944221B2 (ja) 2017-11-20 2021-10-06 ノブメタファーマ カンパニー リミテッド Ｃｈｐ（シクロ−ヒスプロ）を含む骨損失疾患の予防、改善または治療用組成物
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE69411154T2 (de) * 1993-02-22 1998-10-22 Alza Corp Mittel zur oralen gabe von wirkstoffen
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
ATE383169T1 (de) 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (de) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Spritze für medizinische Zwecke
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
AU1189301A (en) 1999-10-29 2001-05-14 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
KR20040007617A (ko) 2001-06-01 2004-01-24 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
CA2453646C (en) * 2001-08-17 2008-09-30 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Also Published As

Publication number Publication date
JP5073153B2 (ja) 2012-11-14
HUP0400120A3 (en) 2012-09-28
EP1397156B1 (en) 2007-03-14
US20080119411A1 (en) 2008-05-22
IL158777A (en) 2012-06-28
KR20040007617A (ko) 2004-01-24
JP2010189423A (ja) 2010-09-02
PL211976B1 (pl) 2012-07-31
KR20120065429A (ko) 2012-06-20
US8153587B2 (en) 2012-04-10
AU2006225157A1 (en) 2006-10-19
BRPI0209748B1 (pt) 2015-11-24
CA2446929C (en) 2013-04-09
JP2005500277A (ja) 2005-01-06
AU2006225157B2 (en) 2009-04-23
NO20035133D0 (no) 2003-11-18
NZ529439A (en) 2005-11-25
ECSP034858A (es) 2004-01-28
SK287697B6 (sk) 2011-06-06
ES2282436T3 (es) 2007-10-16
BR0209748A (pt) 2004-07-27
RU2300392C2 (ru) 2007-06-10
CZ20033232A3 (cs) 2004-06-16
HU229613B1 (en) 2014-03-28
ZA200308625B (en) 2004-07-13
IL158777A0 (en) 2004-05-12
CN1512892A (zh) 2004-07-14
PT1397156E (pt) 2007-05-31
WO2002098453A2 (en) 2002-12-12
DE60218842T2 (de) 2007-12-20
CA2446929A1 (en) 2002-12-12
AU2002344371B2 (en) 2006-06-29
ATE356631T1 (de) 2007-04-15
CO5540323A2 (es) 2005-07-29
KR20090116836A (ko) 2009-11-11
EP1397156A2 (en) 2004-03-17
KR101320817B1 (ko) 2013-10-21
US20040186050A1 (en) 2004-09-23
SK14752003A3 (sk) 2004-06-08
CN101837120A (zh) 2010-09-22
PL364089A1 (en) 2004-12-13
MXPA03011027A (es) 2004-03-19
DE60218842D1 (de) 2007-04-26
CZ307145B6 (cs) 2018-02-07
RU2003136733A (ru) 2005-05-20
NO20035133L (no) 2003-11-18
NO330093B1 (no) 2011-02-14
WO2002098453A3 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
HUP0400120A2 (hu) Mellékpajzsmirigy hormon és kalcitonin orális adagolására szolgáló gyógyászati készítmény
JP2020058871A5 (hu)
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
HUP0303182A2 (hu) Gyógyászati készítmények
HUP0301400A2 (hu) Gyógyszerösszetétel és adagolási forma az alendronát és/vagy más biszfoszfonátoknak a gyomorban történż késleltetett felszabadulására
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
SE9804314D0 (sv) New pharmaceutical formulation
MXPA03006476A (es) Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas.
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
BRPI0508865A (pt) dispositivo de liberação de medicamento visìvel por raio x
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0400386A2 (hu) Cetirizint és pszeudoefedrint tartalmazó tabletta és alkalmazása gyógyszerkészítmények előállítására
EA200401097A1 (ru) Лекарственная форма с регулируемым высвобождением активного ингредиента
HUP0400127A2 (hu) Paracetamolt tartalmazó lenyelhető tabletta
BRPI0513186A (pt) composição medicinal para a administração oral
HUP0202931A2 (hu) Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
MXPA05010707A (es) Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
EA200700524A1 (ru) Препараты для перорального применения с эффектом замедленного действия при приеме api вместе с пищей
NO20044900L (no) Progestagene doseringsenheter

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees